Compare Dishman Pharma with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs AJANTA PHARMA - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA AJANTA PHARMA DISHMAN PHARMA/
AJANTA PHARMA
 
P/E (TTM) x 25.1 24.3 103.2% View Chart
P/BV x 3.3 6.8 49.5% View Chart
Dividend Yield % 0.7 0.5 127.3%  

Financials

 DISHMAN PHARMA   AJANTA PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
AJANTA PHARMA
Mar-19
DISHMAN PHARMA/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs3741,422 26.3%   
Low Rs129898 14.4%   
Sales per share (Unadj.) Rs197.8233.5 84.7%  
Earnings per share (Unadj.) Rs21.244.0 48.2%  
Cash flow per share (Unadj.) Rs34.752.2 66.6%  
Dividends per share (Unadj.) Rs2.009.00 22.2%  
Dividend yield (eoy) %0.80.8 102.4%  
Book value per share (Unadj.) Rs179.9255.1 70.5%  
Shares outstanding (eoy) m80.6988.02 91.7%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x1.35.0 25.6%   
Avg P/E ratio x11.926.4 45.0%  
P/CF ratio (eoy) x7.222.2 32.6%  
Price / Book Value ratio x1.44.5 30.8%  
Dividend payout %9.420.5 46.1%   
Avg Mkt Cap Rs m20,306102,081 19.9%   
No. of employees `0000.86.8 12.2%   
Total wages/salary Rs m5,3554,307 124.3%   
Avg. sales/employee Rs Th19,252.73,022.6 637.0%   
Avg. wages/employee Rs Th6,459.5633.4 1,019.8%   
Avg. net profit/employee Rs Th2,064.1569.1 362.7%   
INCOME DATA
Net Sales Rs m15,96120,554 77.7%  
Other income Rs m265211 125.9%   
Total revenues Rs m16,22620,765 78.1%   
Gross profit Rs m4,1035,664 72.4%  
Depreciation Rs m1,091721 151.3%   
Interest Rs m94412 8,141.4%   
Profit before tax Rs m2,3345,143 45.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6241,273 49.0%   
Profit after tax Rs m1,7113,870 44.2%  
Gross profit margin %25.727.6 93.3%  
Effective tax rate %26.724.8 108.0%   
Net profit margin %10.718.8 56.9%  
BALANCE SHEET DATA
Current assets Rs m11,01811,812 93.3%   
Current liabilities Rs m9,5173,776 252.0%   
Net working cap to sales %9.439.1 24.1%  
Current ratio x1.23.1 37.0%  
Inventory Days Days11077 142.8%  
Debtors Days Days3582 42.7%  
Net fixed assets Rs m16,30414,398 113.2%   
Share capital Rs m161175 92.0%   
"Free" reserves Rs m12,90722,277 57.9%   
Net worth Rs m14,51622,452 64.7%   
Long term debt Rs m4,1897 63,475.8%   
Total assets Rs m29,80526,962 110.5%  
Interest coverage x3.5444.3 0.8%   
Debt to equity ratio x0.30 98,182.2%  
Sales to assets ratio x0.50.8 70.2%   
Return on assets %8.914.4 61.9%  
Return on equity %11.817.2 68.4%  
Return on capital %17.523.0 76.4%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,95210,682 46.4%   
Fx outflow Rs m6972,102 33.2%   
Net fx Rs m4,2558,580 49.6%   
CASH FLOW
From Operations Rs m2,7863,748 74.3%  
From Investments Rs m-1,529-2,228 68.6%  
From Financial Activity Rs m-941-1,475 63.8%  
Net Cashflow Rs m31645 700.0%  

Share Holding

Indian Promoters % 61.4 73.8 83.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 1.6 238.7%  
FIIs % 12.7 7.6 167.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 17.0 130.0%  
Shareholders   46,261 20,968 220.6%  
Pledged promoter(s) holding % 35.8 4.4 814.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   NEULAND LABS  PROCTER & GAMBLE HEALTH  NOVARTIS  UNICHEM LAB  DR. REDDYS LAB  

Compare DISHMAN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Zooms 661 Points, Nifty Ends Above 14,500; M&M and Bajaj Finserv Top Gainers(Closing)

Indian share markets witnessed most of the buying interest during closing hours today and ended on a strong note.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 64.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 64.2% YoY). Sales on the other hand came in at Rs 7 bn (up 15.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 28.9% (Quarterly Result Update)

Aug 24, 2020 | Updated on Aug 24, 2020

For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 45.3% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 45.3% YoY). Sales on the other hand came in at Rs 7 bn (up 32.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 60.8% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 60.8% YoY). Sales on the other hand came in at Rs 7 bn (up 34.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

If the Market Falls, I Will Do This...(Fast Profits Daily)

Apr 1, 2021

What should you do if the market falls? In this video, I'll tell you what I will do.

The Indian Real Estate Party Has Just Begun(Profit Hunter)

Apr 1, 2021

A favourable demand supply scenario makes a strong case for real estate prices.

The Dilemma of Investing in Bharti Airtel(Views On News)

Apr 1, 2021

Rahul Shah on whether Bharti Airtel will emerge as the next big thing in the Indian stock market

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS